A Phase 2 Clinical Trial of the Effectiveness of IRX-2 in Treating Patients With Operable Head and Neck Cancer

2014-08-27 03:49:21 | BioPortfolio


IRX-2 is designed to activate your own body's immune system so that it can better fight the invasion of head and neck cancer. Researchers hope that IRX-2 will help your immune system to mount a more effective attack on the cancer.

IRX-2 has been tested in two clinical studies involving over 50 patients with head and neck cancer. The trials were specifically designed to test the safety of IRX-2. Researchers found that IRX-2 did not appear to have major side effects. In both trials, the researchers found evidence of tumor shrinkage. This may suggest that the immune system was attacking the cancer.

Keep in mind that these are only considered to be preliminary results that provide scientists with enough evidence to continue studying IRX-2. They need to conduct more trials to prove that IRX-2 works and can be made publicly available.


IRX-2 is a biologic product that contains multiple cytokines produced under pharmaceutical standards from phytohemagglutinin (PHA) stimulated mononuclear cells obtained from normal donors. The IRX-2 regimen to be studied is the combination of a 2-week course of IRX-2 itself, an initial dose of cyclophosphamide and a 3-week course of indomethacin and zinc supplementation.

The present study is based in large part on observations made during an exploratory Phase 1-2 study of the safety and efficacy of the IRX-2 regimen performed at the Instituto Nacional de Cancerologia (INCAN), Mexico's National Cancer Institute. Patients with head and neck (HN) squamous cell carcinoma (SCC) were treated with the IRX-2 regimen, some as neoadjuvant therapy prior to surgery and some for advanced disease. Three different doses and dose schedules were studied. In the patients treated preoperatively, evaluation of tumor response was undertaken by comparison of tumor size before and after the IRX-2 regimen. Histological specimens were also graded by percent increase in lymphocyte infiltration and by tumor cell reduction or fragmentation. Evaluation of clinical safety included regular clinical and laboratory evaluations.

This study provided preliminary evidence of the safety and likely efficacy of IRX-2 in the pre-surgical, neoadjuvant treatment of HN SCC. The regimen was well tolerated in most patients, histological and clinical tumor responses were observed and overall survival appeared to be improved compared to similar patients treated at INCAN.

The current study utilizes the same IRX-2 regimen recently evaluated in a Phase 1 trial in patients with recurrent, refractory HN SCC performed at INCAN and the University of Kentucky, where the safety of the IRX-2 regimen was studied and some evidence of clinical activity was observed in 2 of 10 refractory patients.

The current study in patients with newly diagnosed, resectable HN SCC is being conducted to confirm the safety and biological effect of the IRX-2 regimen in a multi-institutional study in the same population to be studied in a planned randomized Phase 3 trial. The primary focus will be on observations made from the start of treatment through the planned surgical resection of the primary tumor.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Squamous Cell Carcinoma of the Head and Neck


IRX-2, Cyclophosphamide, Indomethacin, Zinc, Omeprazole


University of Alabama at Birmingham
United States


Active, not recruiting


IRX Therapeutics

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:49:21-0400

Clinical Trials [4443 Associated Clinical Trials listed on BioPortfolio]

Cyclophosphamide and IRX-2 in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

This randomized phase II trial studies how well cyclophosphamide and IRX-2 work in treating women with cervical squamous intraepithelial neoplasia 3 or squamous vulvar intraepithelial neop...

MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck (SCCHN) is a devastating illness, the treatment of which is associated with significant morbidity. This type of cancer affects 43,000 individua...

Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

The purpose of this study is to further test a combination chemotherapy regimen for the treatment of squamous cell carcinoma of the head and neck and to see if the addition of supportive m...

Study of LN-145 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145) followe...

Preoperative Administration of Olaparib With or Without Cisplatin in Patients Who Are Candidates for Surgery of Carcinoma of Head and Neck

OPHELIA (OlaParib in patients with HEad and neck squamous-celL carcInomA) trial is a Greek, investigator-initiated, randomized open-label window-of-opportunity phase II study. Patients wit...

PubMed Articles [19416 Associated PubMed Articles listed on BioPortfolio]

Combination of serum squamous cell carcinoma antigens 1 and 2 as potential diagnostic marker for sinonasal squamous cell carcinoma and inverted papilloma.

Differentiating inverted papilloma from squamous cell carcinoma (SCC) is sometimes difficult. We evaluated the clinical usefulness of serum SCCA1 and SCCA2 in the management of patients with inverted ...

Combined Metabolo-Volumetric Parameters of F-FDG-PET and MRI Can Predict Tumor Cellularity, Ki67 Level and Expression of HIF 1alpha in Head and Neck Squamous Cell Carcinoma: A Pilot Study.

Our purpose was to evaluate associations of combined F-FDG-PET and MRI parameters with histopathological features in head and neck squamous cell carcinoma (HNSCC).

Refusal of Cancer-Directed Surgery in Head and Neck Squamous Cell Carcinoma Patients.

To investigate the risk factors for refusal of recommended surgery in head and neck squamous cell carcinoma (HNSCC) treatment STUDY DESIGN: Retrospective review of a national database.

Effect of statin use on oncologic outcomes in head and neck squamous cell carcinoma.

Preclinical and early-phase clinical studies have suggested an oncoprotective role of statins in head and neck squamous cell carcinoma (HNSCC). The purpose of this study was to determine whether incid...

Poorly differentiated plasmacytoid squamous cell carcinoma: Case report of a rare malignancy.

Plasmacytoid squamous cell carcinoma is an especially aggressive variant of squamous cell carcinoma that has previously been described in the literature as a variant of oral cancers and most extensive...

Medical and Biotech [MESH] Definitions

Unusual tumor affecting any site of the body, but most often encountered in the head and neck. Considerable debate has surrounded the histogenesis of this neoplasm; however, it is considered to be a myoblastoma of, usually, a benign nature. It affects women more often than men. When it develops beneath the epidermis or mucous membrane, it can lead to proliferation of the squamous cells and mimic squamous cell carcinoma.

A carcinoma derived from stratified squamous epithelium. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.

A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)

More From BioPortfolio on "A Phase 2 Clinical Trial of the Effectiveness of IRX-2 in Treating Patients With Operable Head and Neck Cancer"

Quick Search


Relevant Topics

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Searches Linking to this Trial